Amygdalin Modulates Cell Cycle Regulator Genes in Human Chronic Myeloid Leukemia Cells |
Park, Hae-Jeong
(Kohwang Medical Research Institute, Department of Pharmacology, College of Medicine, Kyung Hee University)
Baik, Haing-Woon (Department of Biochemistry and Molecular Biology, School of Medicine, Eulji University) Lee, Seong-Kyu (Department of Biochemistry and Molecular Biology, School of Medicine, Eulji University) Yoon, Seo-Hyun (Kohwang Medical Research Institute, Department of Pharmacology, College of Medicine, Kyung Hee University) Zheng, Long-Tai (Kohwang Medical Research Institute, Department of Pharmacology, College of Medicine, Kyung Hee University) Yim, Sung-Vin (Kohwang Medical Research Institute, Department of Pharmacology, College of Medicine, Kyung Hee University) Hong, Seon-Pyo (Department of Oriental Pharmaceutical Sciences, College of Pharmacy, Kyung Hee University) Chung, Joo-Ho (Kohwang Medical Research Institute, Department of Pharmacology, College of Medicine, Kyung Hee University) |
1 | Flora, K.P., Cradock, J.C. & Ames, M.M. A simple method for the estimation of amygdalin in the urine. Res. Commun. Chem. Pathol. Pharmacol. 20, 367- 378 (1978) |
2 | Moertel, C.G. et al. A pharmacologic and toxicological study of amygdalin. JAMA 245, 591-594 (1998) DOI |
3 | Kwon, H.Y., Hong, S.P., Hahn, D.H. & Kim, J.H. Apoptosis induction of Persicae Semen extract in human promyelocytic leukemia (HL-60) cells. Arch. Pharm. Res. 26, 157-161 (2003) DOI ScienceOn |
4 | Wang, Z. DNA damage-induced mutagenesis: a novel target for cancer prevention. Mol. Interv. 1, 269-281 (2001) |
5 | Falck, J. et al. The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410, 842-847 (2001) DOI ScienceOn |
6 | Sharifi, N. & Steinman, R.A. Targeted chemotherapy: chronic myelogenous leukemia as a model. J. Mol. Med. 80, 219-232 (2002) DOI ScienceOn |
7 | Koo, J.Y. et al. Quantitative determination of amygdalin epimers from armeniacae semen by liquid chromatography. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 814, 69-73 (2005) DOI ScienceOn |
8 | Sheaff, R.J. et al. Cyclin E-CDK2 is a regulator of p27 (Kip1). Genes Dev. 11, 1464-1478 (1997) DOI ScienceOn |
9 | Savage, D.G. & Antman, K.H. Imatinib mesylate?a new oral targeted therapy. N. Engl. J. Med. 346, 683- 693 (2002) DOI ScienceOn |
10 | Newmark, J. et al. Amygdalin (Laetrile) and prunasin beta-glucosidases: distribution in germ-free rat and in human tumor tissue. Proc. Natl. Acad. Sci. USA. 78, 6513-6516 (1981) |
11 | Goldman, J.M. & Melo, J.V. Chronic myeloid leukemia advances in biology and new approach to treatment. New Engl. J. Med. 349, 1451-1464 (2003) DOI ScienceOn |
12 | Mailand, N. et al. Rapid destruction of human Cdc25A in response to DNA damage. Science 288, 1425-1429 (2000) DOI |
13 | Loda, M. et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3, 231-234 (1997) DOI ScienceOn |
14 | Khandekar, J.D. & Edelman, H. Studies of amygdalin (laetrile) toxicity in rodents. JAMA 242, 169-171 (1979) DOI |
15 | Schwartz, G.K. & Shah, M.A. Targeting the cell cycle: a new approach to cancer therapy. J. Clin. Oncol. 23, 9408-9421 (2005) DOI ScienceOn |
16 | Matsuoka, S. et al. p57Kip2, a structurally distinct member of the p21cip1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev. 9, 650- 662 (1995) DOI |
17 | Mainprize, T.G., Taylor, M.D., Rutka, J.T. & Dirks, P.B. Cip/Kip cell-cycle inhibitors: A neuro-oncological perspective. J. Neurooncol. 51, 205-218 (2001) DOI ScienceOn |
18 | Hirama, T. & Koeffler, H.P. Role of cyclin-dependent kinase inhibitors in the development of cancer. Blood 86, 841-854 (1995) |
19 | Mailand, N. et al. Regulation of G (2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO 21, 5911-5920 (2002) DOI ScienceOn |
20 | Yang, Y.H. et al. Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res. 30, e15 (2002) DOI |
21 | Cho, C.J. et al. Hyundae-Saengyak-Hak. 8th ed. Hak- Chang Press, Seoul, pp. 470-472 (1998) |
22 | Eastman, A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell Biochem. 91, 223-231 (2004) DOI ScienceOn |
23 | Sherr, C.J. & Roberts, J.M. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13, 1501-1512 (1999) DOI ScienceOn |
24 | Lee, M.H., Reynisdottir, I. & Massague, J. Cloning of p57 (KIP2), a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev. 9, 639-649 (1995) DOI ScienceOn |
25 | Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 3, 513-519 (2004) |